MaaT Pharma, Skyepharma Finish Microbiome Ecosystem Therapies Facility

Maat Pharma, a clinical-stage biotech company in the development of Microbiome Ecosystem Therapies (MET) dedicated to improving survival outcomes for patients with cancer, and Skyepharma, a contract development and manufacturing organization (CDMO), that provides innovative solutions for bioproduction as well as complex drugs development and manufacturing, reported that a significant development milestone has been reached with the completion of the 17,200 sq. ft. facility and the transfer of MaaT Pharma’s production and development teams to the new site.

The companies entered a partnership in February 2022 to build the largest cGMP facility, to date, for full ecosystem microbiome therapies in Europe.

According to the company, MaaT Pharma, is one of the few end-to-end microbiome companies that oversees the entire process, including innovative bioprocesses for both donor-derived and co-cultured drug candidates in a GMP environment.

The partnership between the two companies could lead to the creation of a dozen jobs for specialized workers in the industry over the coming years. The therapies demand advanced manufacturing techniques and procedures and will contribute to the growth of the microbiome sector in France. MaaT Pharma and Skyepharma are currently performing quality qualification according to GMP guidelines, with the first production campaign targeted to start in the new plant by the end of Q3 2023.

“With MaaT013, our lead asset currently in Phase 3, and MaaT033, our second drug candidate, nearing launch in a Phase 2b clinical study, we have reached a major milestone that will be fundamental to securing our market access strategy,” said Hervé Affagard, CEO and co-founder of MaaT Pharma. “This new GMP manufacturing facility is a testament to the continued growth of MaaT Pharma. Thanks to our strategic partnership with Skyepharma, we have successfully completed the new infrastructure within a year. I also want to take the opportunity to thank the ABL Europe team who have hosted our GMP production since 2016.”

David Lescuyer, CEO and President of Skyepharma said, “The on-time completion of our first Skyehub facility is a major achievement for Skyepharma and our partner MaaT Pharma. The whole team is proud to have demonstrated the appropriate agility and expertise to deliver this state-of-the-art building and BioCDMO offering in the challenging 12-month timeframe. This reliability is an uncompromising service we want to offer to the biotech partners that are joining us. This is an integral part of the outstanding value accelerator that the Skyehub is providing them.